Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases

Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.

Authors

Brian J Boyarsky¹, Jake A Ruddy¹, Caoilfhionn M Connolly², Michael T Ou¹, William A Werbel³, Jacqueline M Garonzik-Wang¹, Dorry L Segev^{4

5}, Julie J Paik²

Affiliations

¹ Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
² Rheumatology, Johns Hopkins Unveristy, Baltimore, Maryland, USA.
³ Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
⁴ Surgery, Johns Hopkins University, Baltimore, Maryland, USA dorry@jhmi.edu.
⁵ Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

No abstract available

Keywords: COVID-19; antirheumatic agents; autoimmune diseases; vaccination.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Letter

MeSH terms

Antibodies, Viral
Antibody Formation
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Musculoskeletal Diseases*
Rheumatic Diseases*
SARS-CoV-2
Vaccination
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Viral
COVID-19 Vaccines
Vaccines, Synthetic
mRNA Vaccines

Grants and funding